High-Pressure/High-Dose Versus Standard PIPAC in Epithelioid Peritoneal Mesothelioma: Safety, Feasibility, and Outcomes From a Bicentric Comparative Cohort Study.
Nov 11, 2026DOI: 10.1245/s10434-026-20789-9Journal ArticleASO
Written by: Fabian KockelmannNicolas MichotCédric R D DemtröderMaximilian SchmedingMehdi OuaissiJürgen ZierenUrs Giger-Pabst
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a minimally invasive option for peritoneal mesothelioma (PeM) in patients not eligible for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). This bicentric study compared the safety, feasibility, and sex-specific outcomes of standard versus high-pressure/high-dose PIPAC (HP/HD-PIPAC).METHODS: Patients who had non-resectable epithelioid PeM (ePeM) treated with PIPAC at two German centers were retrospectively analyzed. Group 1 received standard PIPAC (cisplatin 7.5 mg/m2 + doxorubicin 1.5 mg/m2, 12 mmHg), and group 2 received HP/HD-PIPAC (cisplatin 20 mg/m2 + doxorubicin 4 mg/m2, 20 mmHg). Procedural outcomes, postoperative complications, interval from diagnosis to first PIPAC, and overall survival (OS) were analyzed. Uni- and multivariable Cox regression analyses were performed to identify factors associated with OS.RESULTS: The 46 patients in the study (group 1: 25 patients; group 2: 21 patients) underwent 120 of 132 scheduled PIPAC procedures. The median OS from diagnosis was 48 months overall: 48 months in group 1, and 36 months in group 2. The interval from diagnosis to first PIPAC was shorter in group 2 (2 vs. 20 months; p = 0.009). Severe complications (Clavien-Dindo ≥III) occurred in 6.2 % of group 1 versus 2.9 % of group 2. The median OS was 106 months for the females versus 35 months for the males (p = 0.064). Multivariable analysis identified female sex, bidirectional treatment, and a longer interval between diagnosis and first PIPAC as independent factors associated with improved OS.CONCLUSIONS: The HP/HD-PIPAC regimen is feasible and safe. Although no significant survival differences were observed between treatment groups, prospective studies are required to define the optimal timing and integration of PIPAC within multimodal treatment strategies. Findings should be interpreted in the context of the retrospective study design.